【摘 要】
:
Background: With the expanding population of colorectal cancer (CRC) survivors in the United States, more attention began to he focused on the second primary malignancy in these CRC survivors.The pres
【机 构】
:
Department of Colorectal Surgery, The Second Affiliated Hospital of Harbin Medical University, 246 X
【出 处】
:
第十二届全国大肠癌学术会议暨江苏省第九届腹腔镜外科会议
论文部分内容阅读
Background: With the expanding population of colorectal cancer (CRC) survivors in the United States, more attention began to he focused on the second primary malignancy in these CRC survivors.The present study attempts to identify the incidence characteristics of second primary malignancy after diagnosis of primary colon and rectal cancer.Methods: 189,890 colon cancer (CC) and 83,802 rectal cancer (RC) cases were identified from Surveillance,Epidemiology and End Results Program (SEER) database.Expected incidence rates were stratified by age, race,stage, calendar year of first CRC diagnosis and latency period since first CRC diagnosis.The standardized incidence ratio (SIR) and excess risk (ER), measures for estimating risk of second primary malignancy, were respectively calculated for CC and RC.Results: Both CC and RC survivors had higher risk of developing second primary malignancy, and CC was higher than RC (SIRCC=1.13;SIRRC=1.05).The risks of cancer of small intestine (SIR=4.03), colon (SIR=1.79)and rectum (SIR=1.80) were the highest in CC patients, and the risk of cancer of rectum (SIR=2.88), small intestine (SIR=2.16) and colon (SIR=1.39) were greatest in RC patients.According to stratified analyses, we also identified the incidence characteristics which contribute to high risk of developing a second primary malignancy, including age between 20 and 40, American Indian/Alaska Native, localized stage, diagnosed at calendar year from 2002 to 2012 and the latency between 12 and 59 months.Conclusion: Both CC and RC survivors remain at higher risk of second primary malignancy.The identification of incidence characteristics of second primary malignancy is extremely essential for continuous cancer surveillance among CRC survivors.
其他文献
目的:探讨是否有更符合CME理念的右半结肠癌根治手术方法.方法:通过对局部解剖学、胚胎学的研究和腹腔镜下手术路径改进:第1步、中央淋巴清扫.第1步包括3个要点:(1)于SMV左缘和SMV血管鞘内间隙,对肠系膜上静脉进行鞘内清扫.(2)自有结肠血管根部至屈氏韧带上缘连线打开系膜,可显露胰腺下缘,确定结肠中血管根部清扫平面;常规清扫14V,切断结肠中动静脉;常规切断胃结肠干.(3)向上清扫胰十二指肠前
急性结肠假性梗阻(acute colonic pseudo-obstruction,ACPO)逐步为临床所认知,但很多方面还有待深入研究,其诊治依然是临床医生的挑战.随着对ACPO病因病理的深入了解,其流行病学也在发生着改变.结肠梗阻患者应警惕ACPO,多可通过影像学检查排除机械性梗阻.早期诊断是关键,保守治疗多可治愈.保守治疗无效者可尝试新斯的明治疗,但目前用药浓度、给药方式尚存争议.对于新斯的
目的:现有的结直肠癌TNM分期系统的单一趋势性存在缺陷.本研究基于单中心数据库对比T-plus分期系统和第七版TNM分期系统用于判断结直肠癌患者预后的优劣.方法:回顾性分析浙江大学医学院附属第二医院于1985年至2011年期间接受根治性手术的非转移性结直肠癌病例数据.共纳入2080例患者进入分析.以总生存率和疾病特异性生存率为因变量,比较T-plus分期系统和第七版TNM分期系统用于判断结直肠癌患
目的:回顾性分析结直肠癌患者合并其他器官恶性肿瘤的发生率、时间关联以及病例特征.方法:回顾分析1996年8月至2014年1月就诊于北京大学肿瘤医院的7840例手术治疗的结直肠癌患者病例资料,比较结直肠癌合并其他器官癌中同时性癌与异时性癌在患者年龄、性别、肿瘤临床分期、分化程度、病理类型和肿瘤发病部位的差异.结果:总计7840例患者中结直肠癌合并其他器官恶性肿瘤156例(2%),其中结直肠单发癌合并
目的:比较中低位直肠癌不同手术方式的治疗效果.方法:回顾性分析2000~2010年间在北京大学肿瘤医院结直肠肿瘤外科行根治性LAR和APR手术直肠癌患者的随访和临床病理资料,并进行多因素分析.结果:一共733例患者被纳入研究,其中APR组183例,LAR组550例.两组患者在年龄、术前CEA水平、环周切缘、脉管癌栓、术后TNM分期,术后辅助化疗方面无显著性差异(P>0.05).APR组患者肿瘤部位
目的:纤溶酶原激活物抑制剂-1 (PAI-1)和蛋白酶激活受体-1(PAR-1)是肠道微环境的重要介质,参与肠道的放射性急性和慢性损伤.为了评价PAI-1和PAR-1的基因多态性是否能够预测直肠癌放射性损伤,我们回顾性地评价了356名接受盆腔放疗的直肠癌患者,分析PAI-1和PAR-1基因多态性与放疗急性毒性反应的关系.方法:对患者放疗后的急性毒性进行评分,包括皮炎、大便失禁、血液学毒性、腹泻和呕
目的:新辅助放化疗后行根治性手术是局部进展期直肠癌(T3-4和/或N+)的标准治疗模式,术后病理为ypT3的患者被认为肿瘤对放化疗反应差.ypT分期显示的是肿瘤在放化疗后的浸润深度,ypT3即肠周脂肪组织中或浆膜下残存肿瘤细胞,但不能显示出肿瘤残留的多少.肿瘤退缩分级(TRG)是根据放化疗后肿瘤细胞数量与纤维化的比例定义的评分体系,多数研究显示其与直肠癌放化疗后的预后相关.本研究旨探讨TRG评分能
目的:急性毒性是直肠癌患者同步放化疗的主要剂量限制性因素,其发生过程与一些致炎性细胞因子相关,包括白介素-1 (interleukin-1,IL-1),白介素-6和肿瘤坏死性因子-α (tumor necrosis factor-alpha,TNF-α).本研究的目的是探讨IL-1,IL-6和TNF基因的单核苷酸多态性是否与直肠癌的放射性急性毒性相关.方法:我们对IL-1,IL-6和TNF 3个基
Purpose;Distant metastasis impaired the value of neoadjunctive chemoradiation therapy (NCRT) for patients who were not pathological completed response.The objective of this study was to evaluate wheth
目的:目前研究表明,不同发病部位的结直肠癌在流行病学、临床病理学特征及分子发病机制方面都存在差异.关于发病部位对于结直肠癌预后的影响,目前的报道并不一致.本研究对右半结肠、左半结肠及直肠3个发病部位肿瘤的临床病理特征、分子标记以及患者预后进行了比较,探讨结直肠癌发病部位对于患者预后的影响.方法:本研究入组了2008年到2014年期间,复旦大学附属肿瘤医院收治的共4426名结直肠癌患者.所有患者均接